In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Corium International Inc. (transdermal delivery technologies for biologics and small-molecule drugs) raised $100mm through the private placement of seven-year 5% convertible senior notes to qualified institutional purchasers. The notes--with interest payable semi-annually in arrears--convert to common at a rate of 58.0552 shares per $1k principal amount, or $17.22 per share. (The company's stock averaged $12.86 at the time of the sale.) Corium will use $56mm of the proceeds to repay a loan to CRG. The company concurrently received FDA feedback on a pilot bioequivalence study (a streamlined version of its previous successful pilot trial) comparing Corium's once-weekly transdermal patch Corplex Donepezil to Eisai's marketed daily oral Alzheimer’s disease drug Aricept (donepezil hydrochloride). The FDA confirmed that its approval would be determined after a review of the NDA, which Corium expects to submit during Q4 2018 using the 505(b)(2) pathway.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?